PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study.

Abstract We analyzed the prevalence of cardiovascular (CV) disease in patients with rheumatoid arthritis (RA) and its association with traditional CV risk factors, clinical features of RA, and the use of disease-modifying antirheumatic drugs (DMARDs) in a multinational cross-sectional cohort of nonselected consecutive outpatients with RA (The Questionnaires in Standard Monitoring of Patients with Rheumatoid Arthritis Program, or QUEST-RA) who were receiving regular clinical care.
PMID
Related Publications

High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors.

Cardiovascular events are not associated with MTHFR polymorphisms, but are associated with methotrexate use and traditional risk factors in US veterans with rheumatoid arthritis.

Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.

Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?

Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study.

Authors

Mayor MeshTerms
Keywords
Journal Title arthritis research & therapy
Publication Year Start




PMID- 18325087
OWN - NLM
STAT- MEDLINE
DA  - 20080627
DCOM- 20080923
LR  - 20151119
IS  - 1478-6362 (Electronic)
IS  - 1478-6354 (Linking)
VI  - 10
IP  - 2
DP  - 2008
TI  - Cardiovascular disease in patients with rheumatoid arthritis: results from the
      QUEST-RA study.
PG  - R30
LID - 10.1186/ar2383 [doi]
AB  - INTRODUCTION: We analyzed the prevalence of cardiovascular (CV) disease in
      patients with rheumatoid arthritis (RA) and its association with traditional CV
      risk factors, clinical features of RA, and the use of disease-modifying
      antirheumatic drugs (DMARDs) in a multinational cross-sectional cohort of
      nonselected consecutive outpatients with RA (The Questionnaires in Standard
      Monitoring of Patients with Rheumatoid Arthritis Program, or QUEST-RA) who were
      receiving regular clinical care. METHODS: The study involved a clinical
      assessment by a rheumatologist and a self-report questionnaire by patients. The
      clinical assessment included a review of clinical features of RA and exposure to 
      DMARDs over the course of RA. Comorbidities were recorded; CV morbidity included 
      myocardial infarction, angina, coronary disease, coronary bypass surgery, and
      stroke. Traditional risk factors recorded were hypertension, hyperlipidemia,
      diabetes mellitus, smoking, physical inactivity, and body mass index. Unadjusted 
      and adjusted hazard ratios (HRs) (95% confidence interval [CI]) for CV morbidity 
      were calculated using Cox proportional hazard regression models. RESULTS: Between
      January 2005 and October 2006, the QUEST-RA project included 4,363 patients from 
      48 sites in 15 countries; 78% were female, more than 90% were Caucasian, and the 
      mean age was 57 years. The prevalence for lifetime CV events in the entire sample
      was 3.2% for myocardial infarction, 1.9% for stroke, and 9.3% for any CV event.
      The prevalence for CV risk factors was 32% for hypertension, 14% for
      hyperlipidemia, 8% for diabetes, 43% for ever-smoking, 73% for physical
      inactivity, and 18% for obesity. Traditional risk factors except obesity and
      physical inactivity were significantly associated with CV morbidity. There was an
      association between any CV event and age and male gender and between
      extra-articular disease and myocardial infarction. Prolonged exposure to
      methotrexate (HR 0.85; 95% CI 0.81 to 0.89), leflunomide (HR 0.59; 95% CI 0.43 to
      0.79), sulfasalazine (HR 0.92; 95% CI 0.87 to 0.98), glucocorticoids (HR 0.95;
      95% CI 0.92 to 0.98), and biologic agents (HR 0.42; 95% CI 0.21 to 0.81; P <
      0.05) was associated with a reduction of the risk of CV morbidity; analyses were 
      adjusted for traditional risk factors and countries. CONCLUSION: In conclusion,
      prolonged use of treatments such as methotrexate, sulfasalazine, leflunomide,
      glucocorticoids, and tumor necrosis factor-alpha blockers appears to be
      associated with a reduced risk of CV disease. In addition to traditional risk
      factors, extra-articular disease was associated with the occurrence of myocardial
      infarction in patients with RA.
FAU - Naranjo, Antonio
AU  - Naranjo A
AD  - Hospital de Gran Canaria Dr, Negrin, University of Las Palmas de Gran Canaria,
      Barranco de la Ballena s/n 35011, Spain. [email protected]
FAU - Sokka, Tuulikki
AU  - Sokka T
FAU - Descalzo, Miguel A
AU  - Descalzo MA
FAU - Calvo-Alen, Jaime
AU  - Calvo-Alen J
FAU - Horslev-Petersen, Kim
AU  - Horslev-Petersen K
FAU - Luukkainen, Reijo K
AU  - Luukkainen RK
FAU - Combe, Bernard
AU  - Combe B
FAU - Burmester, Gerd R
AU  - Burmester GR
FAU - Devlin, Joe
AU  - Devlin J
FAU - Ferraccioli, Gianfranco
AU  - Ferraccioli G
FAU - Morelli, Alessia
AU  - Morelli A
FAU - Hoekstra, Monique
AU  - Hoekstra M
FAU - Majdan, Maria
AU  - Majdan M
FAU - Sadkiewicz, Stefan
AU  - Sadkiewicz S
FAU - Belmonte, Miguel
AU  - Belmonte M
FAU - Holmqvist, Ann-Carin
AU  - Holmqvist AC
FAU - Choy, Ernest
AU  - Choy E
FAU - Tunc, Recep
AU  - Tunc R
FAU - Dimic, Aleksander
AU  - Dimic A
FAU - Bergman, Martin
AU  - Bergman M
FAU - Toloza, Sergio
AU  - Toloza S
FAU - Pincus, Theodore
AU  - Pincus T
CN  - QUEST-RA Group
LA  - ENG
PT  - Journal Article
DEP - 20080306
PL  - England
TA  - Arthritis Res Ther
JT  - Arthritis research & therapy
JID - 101154438
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Glucocorticoids)
SB  - IM
CIN - Arthritis Res Ther. 2008;10(2):105. PMID: 18341711
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/*complications/*drug therapy
MH  - Cardiovascular Diseases/*complications/*epidemiology
MH  - Cross-Sectional Studies
MH  - Female
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Surveys and Questionnaires
PMC - PMC2453774
OID - NLM: PMC2453774
IR  - Hetland ML
FIR - Hetland, Merete Lund
IR  - Linde L
FIR - Linde, Louise
IR  - Horslev-Petersen K
FIR - Horslev-Petersen, Kim
IR  - Hansen TM
FIR - Hansen, Troels Mork
IR  - Knudsen LS
FIR - Knudsen, Lene Surland
IR  - Makinen H
FIR - Makinen, Heidi
IR  - Immonen K
FIR - Immonen, Kai
IR  - Forsberg S
FIR - Forsberg, Sinikka
IR  - Lahteenmaki J
FIR - Lahteenmaki, Jukka
IR  - Luukkainen R
FIR - Luukkainen, Reijo
IR  - Gossec L
FIR - Gossec, Laure
IR  - Dougados M
FIR - Dougados, Maxime
IR  - Maillefert JF
FIR - Maillefert, Jean Francis
IR  - Combe B
FIR - Combe, Bernard
IR  - Sibilia J
FIR - Sibilia, Jean
IR  - Herborn G
FIR - Herborn, Gertraud
IR  - Rau R
FIR - Rau, Rolf
IR  - Alten R
FIR - Alten, Rieke
IR  - Pohl C
FIR - Pohl, Christof
IR  - Burmester GR
FIR - Burmester, Gerd R
IR  - Marsmann B
FIR - Marsmann, Bettina
IR  - Bresnihan B
FIR - Bresnihan, Barry
IR  - Minnock P
FIR - Minnock, Patricia
IR  - Murphy E
FIR - Murphy, Eithne
IR  - Sheehy C
FIR - Sheehy, Claire
IR  - Quirke E
FIR - Quirke, Edel
IR  - Devlin J
FIR - Devlin, Joe
IR  - Alraqi S
FIR - Alraqi, Shafeeq
IR  - Cazzato M
FIR - Cazzato, Massimiliano
IR  - Bombardieri S
FIR - Bombardieri, Stefano
IR  - Ferraccioli G
FIR - Ferraccioli, Gianfranco
IR  - Morelli A
FIR - Morelli, Alessia
IR  - Cutolo M
FIR - Cutolo, Maurizio
IR  - Salaffi F
FIR - Salaffi, Fausto
IR  - Stancati A
FIR - Stancati, Andrea
IR  - Verstappen SM
FIR - Verstappen, Suzan M M
IR  - Jacobs JW
FIR - Jacobs, Johannes W G
IR  - Huisman M
FIR - Huisman, Margriet
IR  - Hoekstra M
FIR - Hoekstra, Monique
IR  - Sierakowski S
FIR - Sierakowski, Stanislaw
IR  - Majdan M
FIR - Majdan, Maria
IR  - Romanowski W
FIR - Romanowski, Wojciech
IR  - Tlustochowicz W
FIR - Tlustochowicz, Witold
IR  - Kapolka D
FIR - Kapolka, Danuta
IR  - Sadkiewicz S
FIR - Sadkiewicz, Stefan
IR  - Zarowny-Wierzbinska D
FIR - Zarowny-Wierzbinska, Danuta
IR  - Titz-Kosko J
FIR - Titz-Kosko, Jadwigi
IR  - Naranjo A
FIR - Naranjo, Antonio
IR  - Calvo-Alen J
FIR - Calvo-Alen, Jaime
IR  - Rodriguez-Lozano C
FIR - Rodriguez-Lozano, Carlos
IR  - Belmonte M
FIR - Belmonte, Miguel
IR  - Baecklund E
FIR - Baecklund, Eva
IR  - Henrohn D
FIR - Henrohn, Dan
IR  - Oding R
FIR - Oding, Rolf
IR  - Liveborn M
FIR - Liveborn, Margareth
IR  - Holmqvist AC
FIR - Holmqvist, Ann-Carin
IR  - Taylor P
FIR - Taylor, Peter
IR  - McClinton C
FIR - McClinton, Catherine
IR  - Woolf A
FIR - Woolf, Anthony
IR  - Chorghade G
FIR - Chorghade, Ginny
IR  - Choy E
FIR - Choy, Ernest
IR  - Kelly S
FIR - Kelly, Stephen
IR  - Gogus F
FIR - Gogus, Feride
IR  - Tunc R
FIR - Tunc, Recep
IR  - Celic S
FIR - Celic, Selda
IR  - Skakic V
FIR - Skakic, Vlado
IR  - Dimic A
FIR - Dimic, Aleksander
IR  - Nedovic J
FIR - Nedovic, Jovan
IR  - Stankovic A
FIR - Stankovic, Aleksandra
IR  - Banja N
FIR - Banja, Niska
IR  - Pincus T
FIR - Pincus, Theodore
IR  - Swearingen C
FIR - Swearingen, Christopher
IR  - Yazici Y
FIR - Yazici, Yusuf
IR  - Bergman M
FIR - Bergman, Martin
IR  - Toloza S
FIR - Toloza, Sergio
IR  - Aguero S
FIR - Aguero, Santiago
IR  - Barrera SO
FIR - Barrera, Sergio Orellana
IR  - Retamozo S
FIR - Retamozo, Soledad
IR  - Alba P
FIR - Alba, Paula
IR  - Lascano C
FIR - Lascano, Cruz
IR  - Babini A
FIR - Babini, Alejandra
IR  - Albiero E
FIR - Albiero, Eduardo
IR  - Sokka T
FIR - Sokka, Tuulikki
EDAT- 2008/03/08 09:00
MHDA- 2008/09/24 09:00
CRDT- 2008/03/08 09:00
PHST- 2007/04/01 [received]
PHST- 2008/03/06 [accepted]
AID - ar2383 [pii]
AID - 10.1186/ar2383 [doi]
PST - ppublish
SO  - Arthritis Res Ther. 2008;10(2):R30. doi: 10.1186/ar2383. Epub 2008 Mar 6.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>